The Health-Maxxing Boom: Inside the Rise of Home Diagnostic Testing
A growing market for mail-in health tests promises personalized insights into everything from gut health to biological age, but experts warn the line between clinical diagnostics and wellness infotainment is increasingly blurred.
The home diagnostics market is booming, with mail-in kits now available for nearly every biomarker imaginable — from gut microbiome composition and cortisol levels to biological age and heart health. According to Precedence Research, the market was worth $6.9 billion last year and is projected to nearly double in size by 2035. The surge represents a step beyond the basic health tracking offered by wearables like Oura Rings and Apple Watches, promising consumers a deeper, data-driven understanding of their bodies.
For many users, the appeal is rooted in a desire for preventive care and control over their own health data. One writer who documented her experience with the trend described collecting cheek swabs, stool samples, saliva, and blood droplets in her home office, all in an effort to assess her biological age, gut health, and stress levels. The process, she noted, was far more complicated than a typical doctor's visit — and it raised a nagging question: would the stress of taking the tests skew the results?
That question points to a broader tension in the industry. While some home tests address critical needs — the FDA last year authorized the first at-home diagnostic for chlamydia, gonorrhea, and trichomoniasis in women, developed by startup Visby Medical, and another company, Teal Health, has an FDA-approved at-home screening for cervical precancer — the majority of companies advertising on social media focus on wellness and preventive health rather than clinical diagnosis. These tests often sidestep FDA regulatory requirements associated with clinical diagnostics, operating in a gray area where results can feel medically useful but are more akin to health «infotainment.»
«We love to learn about ourselves, but there's only so big a market for that, both in terms of absolute numbers and willingness to pay,» says Jenny Rooke, founder and managing director of the biotechnology venture firm Genoa Ventures. Companies that start as infotainment, she says, «end up running into trouble [because] there's an incentive to make stronger and stronger claims to seem more valuable.»
That incentive is visible on platforms like Everlywell, an online store for consumer diagnostics, where shoppers can purchase a hepatitis C test for $69 alongside a gut microbiome test for $485 that promises «AI-powered diet and lifestyle recommendations tailored to you.» The first includes a follow-up with a clinician in case of a positive result; the second reflects still-evolving science about the gut microbiome and its relationship to overall health.
For consumers, the commingling of science and snake oil, clinical and curiosity, can be deeply confusing. Personalized insights often serve as the opening salvo in a campaign to get customers hooked on monthly subscriptions for vitamins, supplements, wellness coaching, and even more tests. The result is a landscape where the line between legitimate medical information and marketing hype is increasingly difficult to discern — and where the promise of optimization comes with a price tag that few can afford.
